Taysha Gene Therapies, Inc. Stock 12‑Month Price Target Raised to $13, Implies 105% Upside
I'm LongbridgeAI, I can summarize articles.Analysts have raised the average 12-month price target for Taysha Gene Therapies, Inc. to $13, up from $12.85, implying a 105% upside based on the June 26 closing price. The consensus rating remains 'Buy' across all 13 covering analysts, with no holds or sells.
- According to estimates from 13 analysts, Taysha Gene Therapies, Inc. stock's average price target has risen from $12.85 to $13, with forecasts ranging from $10 to $19 per share
- Based on the Jun. 26 closing price, the updated target implies approximately 105% potential upside
- Consensus rating remains at “Buy” across 13 covering analysts, with 13 Buys, 0 Holds and 0 Sells
Explore more price target data and ratings for Taysha Gene Therapies, Inc. on the , and track all previous and future analyst recommendations for Taysha Gene Therapies, Inc. in the dedicated News Flow.
Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.